Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A‑443654 is a synthetic small molecule inhibitor of the serine/threonine kinase Akt, also known as protein kinase B. It is an indole-based compound developed for research purposes and has been widely used as a tool compound to study the PI3K/Akt signaling pathway. By inhibiting Akt, A‑443654 blocks downstream signaling involved in cell survival, proliferation, and metabolism. This makes it valuable for investigating cancer biology and other diseases where Akt plays a critical role. The compound is primarily used in preclinical studies and has not advanced to clinical development or approval for therapeutic use[2][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on A-443654.